From AllGov:

Robert Califf, President Barack Obama’s nominee to head the Food and Drug Administration (FDA), is at the center of a European investigation into a blood thinner he helped get approved several years ago.

Before being nominated to run the FDA, Califf helped design and oversee a clinical trial for Xarelto, which thins blood in heart patients. The FDA approved Xarelto in 2011 to prevent blood clots and strokes for individuals suffering from atrial fibrillation. Now, Europe’s equivalent of the FDA, the European Medicines Agency (EMA), is investigating the soundness of that clinical trial.

The clinical trial relied on blood testing devices that were the subject of two FDA warning letters before the trial began and an FDA recall notice after the trial ended, according to the Project on Government Oversight (POGO). Certain devices in the INRatio product line, the warning notice read, could deliver false test results and that use of those devices may “cause severe or life-threatening injuries, including death.”

The EMA has said it “is currently investigating whether the data generated from the INRatio device could have had any impact on the trial results and the extent of this impact, if applicable.”

An FDA staff review of the trial showed that it was biased in favor of approving Xarelto, POGO reported last month. Patients using Xarelto were said to be “at greater risk of harm from stroke and/or bleeding” than if they were treated with warfarin, a blood thinner that has been on the market since the 1950s.



Continue Reading